Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of BMS-986104 in Healthy Male Subjects
NCT02211469Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bms-986104 in rheumatoid arthritis (RA) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of all adverse events (AEs) / serious adverse events (SAEs), Mean difference in ECG heart rate (HR) nadir values and 1 more. Started Aug 2014; status: completed.
02
Drugs
bms-986104
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02211469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211469.